Loading…
← CockpitCompetitor Analysis › ALNY Alnylam Pharmaceuticals, IncOpen in the cockpit ↗

Alnylam Pharmaceuticals, IncALNYCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Pioneer of RNA-interference (RNAi) drugs, selling Onpattro/Amvuttra for ATTR amyloidosis and other genetic diseases.

Momentum laggard 9
Mkt cap
$20.0B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$581M
20-day average traded
Fwd P/E
21.2×
forward earnings
ROIC−WACC
+18.7 pp
WACC 6.9%
Hurdle
-49 pp
Req g minus delivered
Next earnings
92 days
18 Feb 2027
Close · USD$149.40
1D-4.5%
1W-6.5%
1M-35.2%
3M-34.9%
6M-50.0%
YTD-62.4%
1Y-67.6%
ATR %6.7%
Beta0.67
52w lowhigh68.9% off high

What Alnylam Pharmaceuticals does

Pioneer of RNA-interference (RNAi) drugs, selling Onpattro/Amvuttra for ATTR amyloidosis and other genetic diseases.

Sells its own RNAi medicines, led by Amvuttra for ATTR amyloidosis, a buildup of misfolded protein that damages nerves and the heart, and has built its income by widening that drug's approved uses. Its technology is a platform that can be aimed at new targets, which is why it also has partnerships with larger drugmakers such as Roche and Regeneron.

Products and services

  • Amvuttra (ATTR amyloidosis)
  • Onpattro
  • Givlaari (porphyria)
  • Oxlumo (hyperoxaluria)

Customers

  • Cardiologists/neurologists
  • Rare-disease specialists
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • RNAi therapeutics

What could go right

  • Amvuttra label expansion into cardiomyopathy
  • Broader RNAi pipeline maturing to commercial

What could go wrong

  • High R&D/commercial spend ahead of full profitability
  • Competitive entry from other RNAi/antisense players

Moat: wide (IP / patents, process know-how). Founding RNAi patents and manufacturing know-how give a multi-year head start over followers.

Headquarters: Cambridge, Massachusetts, United States · Founded: 2002 · Employees: 2,500

Named competitors

Alnylam Pharmaceuticals at a glance

Size Alnylam Pharmaceuticals (ALNY) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $20.0B, the 489th largest of 3,085 United States companies the cockpit tracks. Shares closed at $149.40 on 18 Nov 2026.

Performance Over six months the shares fell 50.0%, against +5.2% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 56.2% over the last twelve months (peer median +29.3%); the operating margin is 19.5% (peer median 20.2%).

Valuation It trades at 21.2× forward earnings against a peer median of 24.1× (8th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +50%, so the hurdle is -49 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 18.7 points above its cost of capital (6.9% WACC).

Credit Alnylam Pharmaceuticals has 2 bonds outstanding ($1.06B).

Short interest Short interest is 4.1% of the free float (30 Oct 2026).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 107ALNY 50
Six months, rebased to 100: Alnylam Pharmaceuticals against the median of its 20 peers (local-currency closes).

Alnylam Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$5.01B$3.71B$2.25B$1.83B$1.04B
Revenue growth—+65%+23%+76%—
Gross profit$3.87B$3.03B$1.92B$1.52B$869M
EBITDA$1.03B$557M-$120M-$228M-$741M
Net income$2.72B$314M-$278M-$440M-$1.13B
Free cash flow$752M$465M-$42.6M$41.9M-$613M
Capital expenditure$150M$58.7M$34.3M$62.2M$72.1M
Total debt$3.00B$2.97B$2.74B$2.68B$2.61B

Quarterly statements and history in the cockpit →

Alnylam Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%0%1801TORNTPHARMSIG4507VTRSASNDINCYEXELSOBIJAZZ3692ORNAVINSM6446688506IPNROIVLAURUSLABS6990ALNY6-month return →1-month return →
Up and to the right = strong over both horizons. Alnylam Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%0×500×1,000×1801TORNTPHARMSIG4507VTRSASNDEXEL64466990ALNYRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Alnylam Pharmaceuticals is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%1801TORNTPHARMSIG4507VTRSASNDEXELORNAV6446LAURUSLABS6990ALNYGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Alnylam Pharmaceuticals is the large dot.

Alnylam Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (ALNY vs IONS vs PFE vs BBIO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Alnylam Pharmaceuticals ALNY$20.0B-50%+56%20%21.2×0.5%
Ionis Pharmaceuticals IONS$4.56B-64%-1%-59%n/an/a
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
BridgeBio Pharma BBIO$15.2B+14%+167%-37%n/an/a

How Alnylam Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Alnylam Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureALNYPeer medianRank in peer set
1-month return-35.2%+6.1%lowest of 21
6-month return-50.0%+5.2%lowest of 21
Distance from 52-week high-68.9%-9.1%lowest of 21
Revenue growth (TTM)+56.2%+29.3%6th highest of 21
Operating margin19.5%20.2%11th highest of 21
Forward P/E21.2×24.1×8th cheapest of 18
Growth the price implies (Req g, 7 yrs)0.5%11.2%8th least demanding of 18
Growth delivered (Del g)+49.8%+12.5%3rd highest of 18
Hurdle (Req g minus delivered)-49.2 pp-10.8 pp3rd least demanding of 18
ROIC minus cost of capital+18.7 pp+7.2 pp7th highest of 21
EV / EBITDA18.8×22.4×8th cheapest of 16
Net debt / EBITDA-0.6×-0.0×7th least indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%21.2×0.5%+49.8%
Innovent Biologics 1801.HKHong Kong$18.9B+4%+43%17%52.3×11.6%+26.8%
Torrent Pharmaceuticals TORNTPHARM.NSIndia$18.8B+3%+42%22%70.2×37.6%+11.3%
Sigma Healthcare SIG.AXAustralia$22.4B+2%+209%9%38.4×28.9%+26.1%
Shionogi & 4507.TJapan$17.6B+3%+46%29%11.8×0.2%+11.0%
Viatris VTRSUnited States$23.3B+23%+5%11%7.5×11.2%+3.7%
Ascendis Pharma A/S ASNDUnited States$16.9B+12%+94%18%28.0×19.2%+152.4%
Incyte INCYUnited States$24.0B+21%+25%12%15.1×14.2%+14.0%
Exelixis EXELUnited States$16.7B+37%+9%40%17.7×-3.8%+18.6%
Swedish Orphan Biovitrum SOBI.STSweden$16.1B+6%+15%30%24.1×-2.1%+13.1%
Jazz Pharmaceuticals Public JAZZUnited States$15.9B+4%+13%25%9.3×-2.8%+12.5%
Hansoh Pharma 3692.HKHong Kong$25.3B-3%+25%38%25.8×7.9%+10.8%
Orion ORNAV.HEFinland$15.7B+41%+34%38%23.6×-6.2%+11.7%
Insmed INSMUnited States$26.3B+3%+240%-42%n/an/an/a
PharmaEssentia 6446.TWTaiwan$15.0B+67%+78%40%31.9×23.7%+94.8%
Yunnan Baiyao 000538.SZChina$15.0B+11%+5%11%18.3×-0.2%+4.7%
Sichuan Biokin Pharmaceutical 688506.SSChina$14.9B-7%+14%-43%n/an/an/a
Ipsen IPN.PAFrance$14.8B+1%+14%30%10.8×-6.7%+7.2%
Roivant Sciences ROIVUnited States$28.1B+20%+102%-3,234%n/an/an/a
Laurus Labs LAURUSLABS.NSIndia$13.4B+73%+23%24%76.4×51.2%+7.3%
Sichuan Kelun-Biotech Biopharmaceutical 6990.HKHong Kong$13.0B-1%+44%-38%1,176.1×55.3%+33.6%

Alnylam Pharmaceuticals bonds and credit

Alnylam Pharmaceuticals has 2 bonds outstanding with $1.06B face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Alnylam Pharmaceuticals's main competitors?
Named competitors: Ionis Pharmaceuticals (IONS), Pfizer (PFE), BridgeBio Pharma (BBIO). The cockpit's measured peer set (industry) also includes Innovent Biologics (1801.HK), Torrent Pharmaceuticals (TORNTPHARM.NS), Sigma Healthcare (SIG.AX), Shionogi & (4507.T), Viatris (VTRS), Ascendis Pharma A/S (ASND).
Is Alnylam Pharmaceuticals expensive compared with its peers?
On forward p/e it trades at 21.2× against a peer median of 24.1×, 8th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +50%, so the hurdle is -49 pp: the price already allows for a slowdown.
How has Alnylam Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -50.0% against +5.2% for the median peer; over one year -67.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.